Why long-term use of pazopanib/pazopanib is not recommended

Pazopanib is a multi-target tyrosine kinase inhibitor mainly used to treat malignant tumors such as advanced renal cell carcinoma and soft tissue sarcoma. Although it has shown significant efficacy in tumor control, long-term use may bring about a series of safety and tolerability problems, so it is not recommended to be used indefinitely.

First of all, from a toxicity perspective, pazopanib, like many targeted drugs, has a risk of chronic toxicity that cannot be ignored. Common adverse reactions include hypertension, elevated liver enzymes, hypothyroidism, fatigue, diarrhea, and hand-foot syndrome. Among them, hepatotoxicity is particularly important. Some patients may experience elevated levels of ALT, AST or bilirubin during long-term treatment, which may even cause severe liver damage, and may require interruption or termination of treatment.

Secondly, as the medication time is prolonged, some patients may develop drug tolerance, resulting in a gradual weakening of the disease control effect. This acquired resistance mechanism may be related to adaptive changes in tumor cell signaling pathways or activation of bypass pathways. Continued use of pazopanib at this time will not only reduce the efficacy, but may also delay other more effective subsequent treatment strategies.

In addition, long-term use will also increase the financial burden on patients and may affect quality of life. More importantly, current studies mostly focus on short- and medium-term efficacy and safety evaluation, and there is still a lack of clear evidence to support the safety of long-term (such as several years) continuous use. Therefore, clinicians usually recommend regular evaluation of efficacy and tolerability, and comprehensive judgment on whether to continue maintenance treatment.

In general, although pazopanib is an important tool for targeted therapy, it is necessary to be highly vigilant about long-term toxicity and resistance issues during use, emphasize individualized treatment and dynamic evaluation, and avoid long-term blind use to ensure the maximum clinical benefit for patients.

Reference materials:https://www.votrient.com/